$JAZZ · Jazz Pharmaceuticals plc
Jazz Pharmaceuticals filed an 8-K disclosing that its Q3 2026 results will include an estimated ~$755 million pre-tax acquired IPR&D charge tied to the September 15, 2026 acquisition of Actio Biosciences. The non-deductible charge is expected to reduce both GAAP and non-GAAP adjusted EPS by approximately $11.00 per share. The company cautioned that Q3 results are not yet finalized and remain subject to closing procedures.
- Jazz estimates a ~$755 million pre-tax acquired IPR&D charge in Q3 2026 from the Actio Biosciences acquisition completed September 15, 2026.
- The charge is not tax deductible and will reduce both GAAP and non-GAAP adjusted EPS by approximately $11.00 per share.
- The $755 million IPR&D expense represents a substantial hit relative to Jazz's $13.35B market cap.
- Results are preliminary and subject to financial statement closing procedures; final Q3 figures may differ.
- The filing is an 8-K Item 2.02 disclosure, not a full earnings release — full Q3 results are pending.
Stock down 3.88% in regular session to $205.70; extended-hours trading shows minimal additional movement (+0.03% vs filing-time price). The ~$11.00 EPS hit is a large one-time charge that markets are absorbing ahead of full Q3 results.
A ~$755 million one-time charge wiping ~$11.00 off EPS is a material financial event for a $13.35B biopharma — investors need to separate the acquisition noise from core operating performance.
Large acquired IPR&D charges are common in biopharma M&A when the target's lead assets have not yet achieved regulatory approval, reflecting the immediate expensing of in-process R&D under GAAP.
The preliminary IPR&D charge estimate may change upon completion of financial statement closing procedures; actual Q3 results could differ materially from the ~$755 million estimate and ~$11.00 EPS impact disclosed.